Last reviewed · How we verify

Marketed varicella vaccine_Lot 2 — Competitive Intelligence Brief

Marketed varicella vaccine_Lot 2 (Marketed varicella vaccine_Lot 2) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Live attenuated vaccine. Area: Immunology / Infectious Disease.

phase 3 Live attenuated vaccine Varicella-zoster virus (VZV) Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

Marketed varicella vaccine_Lot 2 (Marketed varicella vaccine_Lot 2) — GlaxoSmithKline. This live attenuated varicella-zoster virus vaccine stimulates the immune system to produce antibodies and cell-mediated immunity against varicella (chickenpox).

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Marketed varicella vaccine_Lot 2 TARGET Marketed varicella vaccine_Lot 2 GlaxoSmithKline phase 3 Live attenuated vaccine Varicella-zoster virus (VZV)
Bacille Calmette Guerin (BCG) Bacille Calmette Guerin (BCG) Bandim Health Project marketed Live attenuated vaccine
BCG Solution BCG Solution Alliance for Clinical Trials in Oncology marketed Live attenuated vaccine / Immunotherapy
Rotarix (RV1) Rotarix (RV1) Telethon Kids Institute marketed Live attenuated vaccine Rotavirus VP4 and VP7 surface proteins
Bacillus Calmette-Guerin (BCG) Bacillus Calmette-Guerin (BCG) Massachusetts General Hospital marketed Live attenuated vaccine / Immunotherapy
Attenuated Hepatitis A Vaccine, H2 Strain Attenuated Hepatitis A Vaccine, H2 Strain Jiangsu Province Centers for Disease Control and Prevention marketed Live attenuated vaccine Hepatitis A virus
Bacille Calmette-Guerin Bacille Calmette-Guerin Urological Oncology Council of Northern Tokyo marketed Live attenuated vaccine / Immunotherapeutic agent

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Live attenuated vaccine class)

  1. GlaxoSmithKline · 19 drugs in this class
  2. Merck Sharp & Dohme LLC · 11 drugs in this class
  3. Sanofi Pasteur, a Sanofi Company · 9 drugs in this class
  4. PATH · 5 drugs in this class
  5. Sanofi · 5 drugs in this class
  6. Bandim Health Project · 5 drugs in this class
  7. Centers for Disease Control and Prevention · 3 drugs in this class
  8. International Centre for Diarrhoeal Disease Research, Bangladesh · 3 drugs in this class
  9. Beijing Center for Disease Control and Prevention · 2 drugs in this class
  10. Aga Khan University · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Marketed varicella vaccine_Lot 2 — Competitive Intelligence Brief. https://druglandscape.com/ci/marketed-varicella-vaccine-lot-2. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: